About The Study: In this phase 3 randomized clinical trial that included 1,736 participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab, an antibody designed to clear brain amyloid plaque, significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population.
Authors: John R. Sims, M.D., of Eli Lilly and Company in Indianapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.13239)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the Alzheimer’s Association International Conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.13239?guestAccessKey=855d51a0-c676-46f8-8bb3-1ecaa471d5eb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071723
Journal
JAMA